Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes

Eric J. Bernhard, W. Gillies McKenna, Andrew Hamilton, Said M. Sebti, Yimin Qian, JunMin Wu, Ruth J. Muschel

Research output: Contribution to journalArticle

Abstract

The influence of activated ras oncogenes on the sensitivity of human tumor cells to killing by radiation has been an unresolved question in radiobiology. We have examined this question by measuring the radiation sensitivity of human tumor cell lines with oncogenic mutations in their H- or K-ras genes after treatment with prenyltransferase inhibitors that prevent the posttranslational modification of ras required for its activity. Using two measures of clonogenic survival, we have demonstrated radiosensitization in cell lines with oncogenic H-ras mutations or with oncogenic K-ras mutations when ras processing was inhibited by prenyltransferase inhibitor treatment. In contrast, the inhibition of ras processing in cell lines expressing wild-type ras had no effect on radiation-induced cell death. The prenyltransferase inhibitors themselves inhibited clonogenic survival in some cases, but this inhibition did not correlate with ras mutational status. Although treatment with prenyltransferase inhibitors and radiation resulted in a greater reduction of clonogenicity than either treatment alone in cells with wild-type ras, treatment with both agents had a synergistic effect on cell killing in tumor cells with ras mutations. Our results demonstrate that the inhibition of oncogenic ras activity in human tumor cells can reduce the radiation survival of these cells, suggesting that oncogenic ras can contribute to radiation resistance in human tumors. These results further demonstrate the potential of using prenyltransferase inhibitors in combination with radiotherapy in the treatment of human malignancies.

Original languageEnglish (US)
Pages (from-to)1754-1761
Number of pages8
JournalCancer Research
Volume58
Issue number8
StatePublished - Apr 15 1998

Fingerprint

Prenylation
Dimethylallyltranstransferase
ras Genes
Radiation Tolerance
Tumor Cell Line
Mutation
Radiation
Neoplasms
Therapeutics
Radiobiology
Cell Line
Survival
Radiation Effects
Post Translational Protein Processing
Human Activities
Cell Survival
Cell Death
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bernhard, E. J., McKenna, W. G., Hamilton, A., Sebti, S. M., Qian, Y., Wu, J., & Muschel, R. J. (1998). Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Research, 58(8), 1754-1761.

Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. / Bernhard, Eric J.; McKenna, W. Gillies; Hamilton, Andrew; Sebti, Said M.; Qian, Yimin; Wu, JunMin; Muschel, Ruth J.

In: Cancer Research, Vol. 58, No. 8, 15.04.1998, p. 1754-1761.

Research output: Contribution to journalArticle

Bernhard, EJ, McKenna, WG, Hamilton, A, Sebti, SM, Qian, Y, Wu, J & Muschel, RJ 1998, 'Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes', Cancer Research, vol. 58, no. 8, pp. 1754-1761.
Bernhard, Eric J. ; McKenna, W. Gillies ; Hamilton, Andrew ; Sebti, Said M. ; Qian, Yimin ; Wu, JunMin ; Muschel, Ruth J. / Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. In: Cancer Research. 1998 ; Vol. 58, No. 8. pp. 1754-1761.
@article{76d3596da76c4208a3817775d6dc3fb8,
title = "Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes",
abstract = "The influence of activated ras oncogenes on the sensitivity of human tumor cells to killing by radiation has been an unresolved question in radiobiology. We have examined this question by measuring the radiation sensitivity of human tumor cell lines with oncogenic mutations in their H- or K-ras genes after treatment with prenyltransferase inhibitors that prevent the posttranslational modification of ras required for its activity. Using two measures of clonogenic survival, we have demonstrated radiosensitization in cell lines with oncogenic H-ras mutations or with oncogenic K-ras mutations when ras processing was inhibited by prenyltransferase inhibitor treatment. In contrast, the inhibition of ras processing in cell lines expressing wild-type ras had no effect on radiation-induced cell death. The prenyltransferase inhibitors themselves inhibited clonogenic survival in some cases, but this inhibition did not correlate with ras mutational status. Although treatment with prenyltransferase inhibitors and radiation resulted in a greater reduction of clonogenicity than either treatment alone in cells with wild-type ras, treatment with both agents had a synergistic effect on cell killing in tumor cells with ras mutations. Our results demonstrate that the inhibition of oncogenic ras activity in human tumor cells can reduce the radiation survival of these cells, suggesting that oncogenic ras can contribute to radiation resistance in human tumors. These results further demonstrate the potential of using prenyltransferase inhibitors in combination with radiotherapy in the treatment of human malignancies.",
author = "Bernhard, {Eric J.} and McKenna, {W. Gillies} and Andrew Hamilton and Sebti, {Said M.} and Yimin Qian and JunMin Wu and Muschel, {Ruth J.}",
year = "1998",
month = "4",
day = "15",
language = "English (US)",
volume = "58",
pages = "1754--1761",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes

AU - Bernhard, Eric J.

AU - McKenna, W. Gillies

AU - Hamilton, Andrew

AU - Sebti, Said M.

AU - Qian, Yimin

AU - Wu, JunMin

AU - Muschel, Ruth J.

PY - 1998/4/15

Y1 - 1998/4/15

N2 - The influence of activated ras oncogenes on the sensitivity of human tumor cells to killing by radiation has been an unresolved question in radiobiology. We have examined this question by measuring the radiation sensitivity of human tumor cell lines with oncogenic mutations in their H- or K-ras genes after treatment with prenyltransferase inhibitors that prevent the posttranslational modification of ras required for its activity. Using two measures of clonogenic survival, we have demonstrated radiosensitization in cell lines with oncogenic H-ras mutations or with oncogenic K-ras mutations when ras processing was inhibited by prenyltransferase inhibitor treatment. In contrast, the inhibition of ras processing in cell lines expressing wild-type ras had no effect on radiation-induced cell death. The prenyltransferase inhibitors themselves inhibited clonogenic survival in some cases, but this inhibition did not correlate with ras mutational status. Although treatment with prenyltransferase inhibitors and radiation resulted in a greater reduction of clonogenicity than either treatment alone in cells with wild-type ras, treatment with both agents had a synergistic effect on cell killing in tumor cells with ras mutations. Our results demonstrate that the inhibition of oncogenic ras activity in human tumor cells can reduce the radiation survival of these cells, suggesting that oncogenic ras can contribute to radiation resistance in human tumors. These results further demonstrate the potential of using prenyltransferase inhibitors in combination with radiotherapy in the treatment of human malignancies.

AB - The influence of activated ras oncogenes on the sensitivity of human tumor cells to killing by radiation has been an unresolved question in radiobiology. We have examined this question by measuring the radiation sensitivity of human tumor cell lines with oncogenic mutations in their H- or K-ras genes after treatment with prenyltransferase inhibitors that prevent the posttranslational modification of ras required for its activity. Using two measures of clonogenic survival, we have demonstrated radiosensitization in cell lines with oncogenic H-ras mutations or with oncogenic K-ras mutations when ras processing was inhibited by prenyltransferase inhibitor treatment. In contrast, the inhibition of ras processing in cell lines expressing wild-type ras had no effect on radiation-induced cell death. The prenyltransferase inhibitors themselves inhibited clonogenic survival in some cases, but this inhibition did not correlate with ras mutational status. Although treatment with prenyltransferase inhibitors and radiation resulted in a greater reduction of clonogenicity than either treatment alone in cells with wild-type ras, treatment with both agents had a synergistic effect on cell killing in tumor cells with ras mutations. Our results demonstrate that the inhibition of oncogenic ras activity in human tumor cells can reduce the radiation survival of these cells, suggesting that oncogenic ras can contribute to radiation resistance in human tumors. These results further demonstrate the potential of using prenyltransferase inhibitors in combination with radiotherapy in the treatment of human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0032522849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032522849&partnerID=8YFLogxK

M3 - Article

C2 - 9563495

AN - SCOPUS:0032522849

VL - 58

SP - 1754

EP - 1761

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8

ER -